Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT02133157
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
71
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumor
Interventions
DRUG:
Sulfatinib
Sponsor
Hutchison Medipharma Limited